Analysis

Shkreli's Brazen Defiance May Lead To Harsher Sentence

By Stewart Bishop · August 7, 2017, 9:06 PM EDT

Public statements from former Turing Pharmaceuticals and Retrophin CEO Martin Shkreli deriding the prosecution's securities fraud case against him may come back to bite him at sentencing, legal experts said Monday....

To view the full article, register now.